Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-01-04
Based on 559 first isolates · SURG · Skin / wound infection · 2025-01-05 → 2026-01-04
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 55 % (50 %–59 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (12 %), Proteus mirabilis (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
55 %
34 %
n = 32
meropenem MEM
trend · Pseudomonas aeruginosa reserve
44 %
63 %
n = 32
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
42 %
25 %
n = 32
42 %
63 %
n = 32
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
41 %
63 %
n = 32
ceftriaxone CRO
trend · Escherichia coli
28 %
44 %
n = 32
25 %
41 %
n = 32
22 %
25 %
n = 32
12 %
19 %
n = 32
mecillinam MEC
not for this site
0 %
0 %
n = 32
trimethoprim TMP
not for this site
0 %
0 %
n = 32
nitrofurantoin NIT
not for this site
0 %
0 %
n = 32

Most likely organisms for this profile

Staphylococcus aureus
44 %
Pseudomonas aeruginosa
14 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
9 %
Citrobacter freundii
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.